Assessment of the Analgesic Effects of PF-06273340 in Healthy Volunteers Using Evoked Pain Endpoints

Phase 1 Completed 20 enrolled Pfizer

RandomizedCrossoverDouble-blindBasic science

Summary

This study will examine the activity of 2 different doses of PF-06273340 on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects

Timeline

Start: 2014-10
Primary completion: 2014-12
Completion: 2014-12

Publications

Loudon P, Siebenga P, Gorman D, Gore K, Dua P, van Amerongen G, Hay JL, Groeneveld GJ, Butt RP. Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models. Br J Clin Pharmacol. 2018 Feb;84(2):301-309. doi: 10.1111/bcp.13448. Epub 2017 Nov 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Ibuprofen	Small molecule	600 mg	—
Subject	PF-06273340	Small molecule	50 mg	Oral
Subject	PF-06273340	Small molecule	400 mg	Oral
Comparator	Pregabalin	Small molecule	300 mg	—

Indications

No indication recorded.